# A Study to Evaluate the Efficacy and Safety of Ibrutinib, in Patients With Mantle Cell Lymphoma Who Progress After Bortezomib Therapy

> **NCT01599949** · PHASE2 · COMPLETED · sponsor: **Janssen Research & Development, LLC** · enrollment: 120 (actual)

## Conditions studied

- Mantle Cell Lymphoma

## Interventions

- **DRUG:** Ibrutinib

## Key facts

- **NCT ID:** NCT01599949
- **Lead sponsor:** Janssen Research & Development, LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-08
- **Primary completion:** 2015-05
- **Final completion:** 2015-05
- **Target enrollment:** 120 (ACTUAL)
- **Last updated:** 2016-06-01

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01599949

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01599949, "A Study to Evaluate the Efficacy and Safety of Ibrutinib, in Patients With Mantle Cell Lymphoma Who Progress After Bortezomib Therapy". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT01599949. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*